ÇѸ²´ëÇб³¼º½Éº´¿ø

ÀÌ¿µ±¸ ±³¼ö

1577-5587 uroyglee@hallym.or.kr
  • Àü¹®¼¾ÅÍ ·Îº¿¼ö¼ú¼¾ÅÍ ¾Ï¼¾ÅÍ
  • Áø·á°ú ºñ´¢ÀÇÇаú

Àü¹®Áø·áºÐ¾ß

·Îº¿¼ö¼ú(Àü¸³¼±¾Ï, ¹æ±¤¾Ï Àΰø¹æ±¤ ¼ö¼ú, ½ÅÀå¾Ï, ½Å¿ì¿ä°ü¾Ï, ºÎ½ÅÁ¾¾ç, ½Å¿ì¼ºÇü¼ú), Àü¸³¼± ºñ´ëÁõ, ºñ´¢±â Á¾¾ç , ¿ä·Î°á¼®, ¿ä½Ç±Ý(³², ¿©)

ÀüÈ­ ¿¹¾à 1577-5587
±³¼ö´Ô»çÁø

(ÁÖ°£) Áø·á½Ã°£Ç¥ (2024-05-13 ~ 2024-05-18)

Áø·á½Ã°£Ç¥
Áø·á½Ã°£ ¿ù È­ ¼ö ¸ñ ±Ý Åä
¿ÀÀü ¼¾ÅÍÁø·á¼¾ÅÍÁø·á¼¾ÅÍÁø·á
¿ÀÈÄ ¼¾ÅÍÁø·á
±³¼ö´Ô »çÁø

±âº»Á¤º¸

ÇзÂ

ÇзÂ

1983Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ Á¹¾÷

1988Áß¾Ó´ëÇб³ ÀÇÇм®»ç

1994Áß¾Ó´ëÇб³ ÀÇÇйڻç

1998University of Michigan Cancer Center Àå±â ÇØ¿Ü ¿¬¼ö

2005NYPH Columbia University, NYPH Cornell Universty ÇØ¿Ü ¿¬¼ö ·Îº¿¼ö¼ú

2007NYPH Cornell Unversity ·Îº¿¼ö¼ú ÇØ¿Ü ¿¬¼ö ·Îº¿¼ö¼ú

°æ·Â

°æ·Â

îñ ÇѸ²´ëÇб³°­³²¼º½Éº´¿øÀå

úÞ ÇѸ²´ëÇб³°­³²¼º½Éº´¿ø ºñ´¢ÀÇÇаú ±³¼ö

úÞ ÇѸ²´ëÇб³°­³²¼º½Éº´¿ø ·Îº¿¼ö¼ú¼¾ÅÍ ¼¾ÅÍÀå

úÞ ´ëÇѺñ´¢ÀÇÇÐȸ ºÎȸÀå

úÞ ´ëÇѺñ´¢ÀÇÇÐȸ º¸ÇèÁ¤Ã¥»ç¾÷´ÜÀå

úÞ ´ëÇѺñ´¢ÀÇÇÐȸ ÆòÀÇ¿ø(ÀÌ»ç)

úÞ ´ëÇÑÀÓ»óº¸ÇèÀÇÇÐȸ ÀÌ»çÀå

úÞ ´ëÇѺ´¿øÇùȸ º¸ÇèºÎÀ§¿øÀå

úÞ º¸°Çº¹ÁöºÎ °Ç°­º¸ÇèºÐÀïÁ¶Á¤À§¿øȸ À§¿ø

úÞ º¸°Çº¹ÁöºÎ »ó´ë°¡Ä¡ ±âȹ´Ü À§¿ø

úÞ °Ç°­º¸Çè½É»çÆò°¡¿ø Áø·á½É»çÆò°¡À§¿ø ÀÓ»óÀü¹®°¡ Á¶Á¤ÆгΠÀ§¿øÀå

úÞ °Ç°­º¸Çè½É»çÆò°¡¿ø ÀÇ·áÆò°¡Á¶Á¤À§¿øȸ À§¿ø

úÞ °Ç°­º¸Çè½É»çÆò°¡¿ø Æò°¡±âȹºÐ°ú À§¿øȸ À§¿ø

úÞ °Ç°­º¸Çè½É»çÆò°¡¿ø Áø·á½É»çÆò°¡À§¿øȸ ºñ»ó±Ù ½É»çÀ§¿ø

úÞ Çѱ¹ÀǾàÇ° ¾ÈÀü°ü¸®¿ø DUR ºÐ°úÀ§¿ø

úÞ Åë°èû Áúº´ºÐ·ù»ó´ã¼¾ÅÍ Àü¹®À§¿ø

2009 ~ 2016ÇѸ²´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢ÀÇÇб³½Ç ÁÖÀÓ±³¼ö

2013 ~ 2015ÇѸ²´ëÇб³°­³²¼º½Éº´¿ø ºñ´¢ÀÇÇаú °úÀå

2002 ~ 2006ÇѸ²´ëÇб³°­³²¼º½Éº´¿ø CS/QI À§¿øÀå

2006 ~ 2008ÇѸ²´ëÇб³°­³²¼º½Éº´¿ø ±âȹ½ÇÀå

2008 ~ ÇѸ²´ëÇб³ ÀÇ·á¿ø È«º¸À§¿øȸ À§¿øÀå

2008 ~ 2014ÇѸ²´ëÇб³°­³²¼º½Éº´¿ø Àǹ«±â·ÏÀ§¿øȸ À§¿øÀå

2008 ~ 2016ÇѸ²´ëÇб³°­³²¼º½Éº´¿ø Á¾¾çÀ§¿øȸ À§¿øÀå

2008 ~ 2016ÇѸ²´ëÇб³°­³²¼º½Éº´¿ø ³ª´®ºÀ»ç´Ü ´ÜÀå

2010 ~ 2014´ëÇÑÀÓ»óº¸ÇèÀÇÇÐȸ ÇмúÀÌ»ç

2014 ~ 2018´ëÇÑÀÓ»óº¸ÇèÀÇÇÐȸ Ãѹ«ÀÌ»ç

ÇÐȸȰµ¿

ÇÐȸȰµ¿

2014 ~ úÞ ´ëÇѺñ´¢ÀÇÇÐȸ ºÎȸÀå

2010 ~ úÞ ´ëÇѺñ´¢ÀÇÇÐȸ ÆòÀÇ¿ø

2014 ~ úÞ ´ëÇѺñ´¢ÀÇÇÐȸ º¸ÇèÁ¤Ã¥»ç¾÷´ÜÀå

2018 ~ úÞ ´ëÇÑ ÀÓ»óº¸ÇèÀÇÇÐȸ ÀÌ»çÀå

2015 ~ úÞ ´ëÇѺñ´¢ÃÊÀ½ÆÄÇÐȸ °í¹®

1998 ~ úÞ ¹Ì±¹ºñ´¢±â°úÇÐȸ( AUA) Á¤È¸¿ø

2004 ~ úÞ ¼¼°è ºñ´¢±â°úÇÐȸ (SIU) Á¤È¸¿ø

2012 ~ úÞ À¯·´ ºñ´¢±â°úÇÐȸ (EAU) Á¤È¸¿ø

2008 ~ 2014´ëÇѺñ´¢ÀÇÇÐȸ º¸ÇèÀÌ»ç

2016 ~ 2018´ëÇÑÀÇ»çÇùȸ »ó´ë°¡Ä¡À§¿øȸ »ó´ë°¡Ä¡¿¬±¸´ÜÀå

2008 ~ 2021´ëÇÑÀÇ»çÇùȸ »ó´ë°¡Ä¡À§¿øȸ »ó´ë°¡Ä¡¿¬±¸´ÜÀ§¿ø

2004 ~ 2018´ëÇѺñ´¢±âÁ¾¾çÇÐȸ ÀÌ»ç

2004 ~ 2010´ëÇѺñ´¢±âÁ¾¾çÇÐȸ º¸ÇèÀÌ»ç

2002 ~ 2018´ëÇÑÀü¸³¼±ÇÐȸ ÀÌ»ç

2012 ~ 2014´ëÇÑ¿ä·Î»ý½Ä±â °¨¿°ÇÐȸ °¨»ç

2012 ~ 2015´ëÇѺñ´¢ÃÊÀ½ÆÄÇÐȸ °¨»ç

2014 ~ 2018´ëÇѺñ´¢³ëÀοä¾çÇÐȸ °í¹®

2019 ~ 2021´ëÇѺñ´¢Á¾¾çÇÐȸ ±¹¼ÒÄ¡·á¿¬±¸È¸ °¨»ç

¼ö»óÀÌ·Â

¼ö»óÀÌ·Â

2022.04°úÇбâ¼úÁ¤º¸Åë½ÅºÎ Àå°ü ǥâ

2021.12º¸°Çº¹ÁöºÎ Àå°ü ǥâ

2013.10´ëÇÑÀü¸³¼±ÇÐȸ Çмú»ó ¼ö»ó ¡®ÀüÀ̼º Àü¸³¼±¾ÏȯÀÚ¿¡¼­ º´¿ëÈ£¸£¸ó Ä¡·áÈÄ 2 °³¿ù ÈÄ PSA Ä¡ÀÇ ¿¹ÈÄÀû ÀÇÀÇ¡¯

2006.11´ëÇѺñ´¢ÀÇÇÐȸ ¿ì¼ö¿¬Á¦ ¹ßÇ¥»ó ¡® Gold MArker¸¦ ÀÌ¿ëÇÑ Àü¸³¼±¾Ï ȯÀÚÀÇ ¿µ»óÀ¯µµ ¹æ»ç¼± Ä¡·á¡¯

2007.08´ëÇѺñ´¢Á¾¾çÇÐȸ °ø¸ð ³í¹®Çмú»ó ¼ö»ó ¡®½ÅÀåÀÇ Åä¸í À°Á¾ ¼¼Æ÷ÁÖ CCSK-2ÀÇ È®¸³ ¹× ±Ô¸í¡¯

2010.03Mighty Hallym Global Player Award (·Îº¿¼ö¼úºÎºÐ)

2005Mighty Hallym CS °ø·Î»ó

1986¼º½É ¹«±ÃÈ­»ó ¼ö»ó ¡®191 ·¹ÀÇ ¿äµµÇùÂø ¼ö¼ú Ä¡Ç衯

1996õÁÖ±³ ¼­¿ï´ë±³±¸ »êÇÏ ¿µ¼¼¹Î ¹«·áÁø·á¼Ò Àü.Áø.»ó. ÀÇ¿ø Àå±â ÀÇ·áºÀ»ç»ó( Ãß±â°æ ±è¼öȯ )

2004õÁÖ±³ ¼­¿ï´ë±³±¸ »êÇÏ ¿µ¼¼¹Î ¹«·áÁø·á¼Ò Àü.Áø.»ó. ÀÇ¿ø Àå±â ÀÇ·áºÀ»ç»ó ( Ãß±â°æ ±è¼öȯ )

³í¹®

📌 ±¹³»ÇÐȸÁö ¹ßÇ¥³í¹®
1. Laparoscopic ureteroureterostomy and transvaginal ureterectomy for complete duplicated ureters. J Endourol. 2014. Jul;28(7):825-30.

2. Our experiences with robot-assisted laparoscopic radical cystectomy: orthotopic neobladder by the suprapubic incision method. Korean J Urol. 2012 Nov;53(11):766-73.

3. Background and Validity of the Promotion of Prostate-Specific Antigen Based Prostate Cancer Screening to National Cancer Screening Program. Korean J Urol Oncol 2010 Apr; 8(1): 1-9.

4. Robot-assisted radical cystectomy and pelvic lymph node dissection: a multi-institutional study from Korea. J Endourol. 2010. Sep;24(9):1435-40

5. Voiding Pattern and Incontinence after Orthotopic Ileal Neobladder in Male Patients
The Korean Journal of Urology 2007 Jan 048(01): 12-17.

6. Risk Factors of Ileus following Radical Cystectomy. The Korean Journal of Urology 2007 Dec 048(12): 1236-1241.

7. Establishment and Characterization of a Renal Clear Cell Sarcoma Cell Line, CCSK-2. Korean J Urol Oncol 2007 Dec; 5(3): 122-133

8. Effect of Galectin-3 Gene Transfer for the Apoptosis and Cell Growth of the Prostate Cancer Cell Line(LNCaP Cells). The Korean Journal of Urology 2005 Dec 046(12): 1354-1359.

9. Effect of Prostate Specific Membrane Antigen on Angiogenesis. The Korean Journal of Urology 2004 Nov 045(11): 1162-1166.

10. Prognostic Significance of Prostate-specific Antigen Level Two Months after Maximal Androgen Blockade in Metastatic Prostate Cancer. Korean J Urol 2003 Sep 044(09): 855-860.

11. The Molecular Biologic Study about the Role of Deubiquitination Gene in Bladder Tumor Progression. Korean J Urol 2002 Dec 043(12): 1019-1023.

12. Prostate Specific Membrane Antigen Expression in Renal Cell Carcinoma and Transitional Cell Carcinoma. Korean J Urol 2001 Jul 042(07): 679-684.

13. MIM, a potential metastasis suppressor gene in bladder cancer. Neoplasia. 2002 Jul-Aug;4(4):291-4.

14. Establishment and characterization of a new human prostatic cancer cell line: DuCaP. In Vivo. 2001 Mar-Apr;15(2):157-62.

15. VCaP, a cell-based model system of human prostate cancer. In Vivo. 2001 Mar-Apr;15(2):163-8.

📌 Àú¼­/Àú¼ú
´ëÇѺñ´¢±â°úÇÐ 4,5ÆÇ
Àü¸³¼±ºñ´ëÁõ

📌 ¹æ¼Û ¹× À¯Æ©ºê ¿µ»ó

1. ÇѸ²´ëÇб³°­³²¼º½Éº´¿ø ·Îº¿¼ö¼ú¼¾ÅÍ ¼Ò°³
2. Èí¿¬À» ÇÑ´Ù¸é ¹æ±¤¾ÏÀ» Á¶½ÉÇ϶ó! | ºñ´¢ÀÇÇаú ÀÌ¿µ±¸ ±³¼ö
3. ¹æÄ¡µÇ°í ÀÖ´Â ¿ä¾çº´¿ø ³ëÀÎȯÀÚ '¹è´¢ÀαÇ' [¸ÅÀÏ°æÁ¦]
4. [¾Æ¸®¶û½ºÆä¼È] ¼¼°è ·Îº¿°úÀÇ °øÁ¸: ´ÙºóÄ¡Xi : 27ºÐ 45ÃÊ ~
5. [KBS »ý·Îº´»çÀÇ ºñ¹Ð 732ȸ] 2020 ¹æ»ç¼± Ä¡·á ÷´Ü º¸°í¼­ : 13ºÐ 30ÃÊ ~
6. ¼Òº¯¿¡¼­ ÇÇ°¡ ¼¯¿© ³ª¿Â´Ù¸é?! ½ÅÀå¾ÏÀ» ÀǽÉÇغ¸¾Æ¾ß ÇÕ´Ï´Ù!


°Ç°­Á¤º¸ µ¿¿µ»ó